Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy

N/AActive Not RecruitingNCT05506254

Alexion Pharmaceuticals, Inc.4 enrolled

Overview

This is a non-interventional long-term follow-up study of patients who have participated in LogicBio studies for the treatment of MMA and received hLB-001

Patients will be followed for a period of 15 years which includes the duration of time that the patient was in the treatment study.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Methylmalonic Acidemia

Interventions

hLB-001DRUG

hLB-001 gene therapy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participant has previously participated in a LogicBio clinical trial and received hLB-001. Exclusion Criteria: * None

Locations (4)

Clinical Trial Site

Atlanta, Georgia, United States

Clinical Trial Site

Pittsburgh, Pennsylvania, United States

Clinical Trial Site

Nashville, Tennessee, United States

Clinical Trial Site

Seattle, Washington, United States

Outcomes

Primary Outcomes

Incidence of treatment emergent adverse events

Time frame: 15 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.